VRTX240719P457500
- 0.84
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Express News | Vertex Seeks Court Confirmation That Financial Support Program For Fertility Services Related To Casgevy Does Not Violate Federal Anti-Kickback Laws; Disagrees With Regulator's Conclusion And Seeks Federal Court Ruling
Express News | Vertex Disagrees With the Regulator's Conclusion That the Program Would Implicate Anti-Kickback Laws, and Wants a Federal Court to Rule Otherwise
Express News | Vertex Is Seeking Confirmation That Its Program for Providing Financial Support for Fertility Services Related to Casgevy Would Not Violate Federal Anti-Kickback Laws
Express News | Vertex Pharmaceuticals Sues U.S. Department of Health and Human Services in Connection With Casgevy Gene Editing Therapy
Express News | Health Canada Grants Marketing Authorization for Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Insider Sale: EVP and CMO Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
On July 10, 2024, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 2,280 shares of the company.
Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals
In the preceding three months, 13 analysts have released ratings for Vertex Pharmaceuticals (NASDAQ:VRTX), presenting a wide array of perspectives from bullish to bearish.The table below provides a
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 -7.67% Morgan Stanley $402 → $455 Maintains Equal-Weight 06/27/2024 10.59% Redburn Atlantic → $
Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
New York, USA, July 11, 2024 (GLOBE NEWSWIRE) -- Cystic Fibrosis Market is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech,
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 28% Discount?
Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.
Express News | Vertex Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $455 From $402
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402
Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $577, according to analysts by Capital IQ.Price: 491.00, Change: -0.62, Percent Change: -0.13
Check Out What Whales Are Doing With VRTX
High-rolling investors have positioned themselves bullish on Vertex Pharmaceuticals (NASDAQ:VRTX), and it's important for retail traders to take note.\This activity came to our attention today
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 1.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 10, $Vertex Pharmaceuticals(VRTX.US)$ Officer Bozic Carmen intends to sell 2,280 shares of its common stock on Jul 10, with a total market value of approximately $1.11
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $485.99, marking a +0.85% move from the previous day.
Vertex Pharmaceuticals Hits 4-week High
Express News | Vertex Pharmaceuticals Inc : RBC Raises Target Price to $431 From $421
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).